(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote in favor of your Favored kind of pasta - 2'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- 3RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- 4Well known Travel Booking Locales: What's Your Pick?
- 5U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- 5 Great and High Evaluated Scene Configuration Administrations For 2024
- First Alert: Light snow through this evening
- What to know as New York City nurses strike for a 3rd day
- The Universe of Impeccable Pearls: A Manual for Valuable Gems
- Ways to track down the Right Criminal Legal counselor
- 10 times the sky amazed us in 2025
- Remote Headphones: Upgrade Your Sound Insight
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
